PT  - JOURNAL ARTICLE
AU  - Smith, David R. M.
AU  - Duval, Audrey
AU  - Zahar, Jean Ralph
AU  - ,
AU  - Opatowski, Lulla
AU  - Temime, Laura
TI  - Rapid antigen testing as a reactive response to surges in nosocomial SARS-CoV-2 outbreak risk
AID  - 10.1101/2021.08.13.21261968
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.13.21261968
4099  - http://medrxiv.org/content/early/2021/12/22/2021.08.13.21261968.short
4100  - http://medrxiv.org/content/early/2021/12/22/2021.08.13.21261968.full
AB  - Healthcare facilities are vulnerable to SARS-CoV-2 introductions and subsequent nosocomial outbreaks. Antigen rapid diagnostic testing (Ag-RDT) is widely used for population screening, but its health and economic benefits as a reactive response to local surges in outbreak risk are unclear. We simulate SARS-CoV-2 transmission in a long-term care hospital with varying COVID-19 containment measures in place (social distancing, face masks, vaccination). Across scenarios, nosocomial incidence is reduced by up to 40-47% (range of means) with routine symptomatic RT-PCR testing, 59-63% with the addition of a timely round of Ag-RDT screening, and 69-75% with well-timed two-round screening. For the latter, a delay of 4-5 days between the two screening rounds is optimal for transmission prevention. Screening efficacy varies depending on test sensitivity, test type, subpopulations targeted, and community incidence. Efficiency, however, varies primarily depending on underlying outbreak risk, with health-economic benefits scaling by orders of magnitude depending on the COVID-19 containment measures in place.Competing Interest StatementLO reports a research grant from Pfizer outside the submitted work. JRZ has received funding from Pfizer and Merck Sharp and Dohme for a research project through his institution, outside of the submitted work. All other authors report no other conflicts of interest.Funding StatementThe work was supported directly by internal resources from the French National Institute for Health and Medical Research (Inserm), the Institut Pasteur, the Conservatoire National des Arts et Metiers, and the University of Versailles-Saint-Quentin-en-Yvelines / University of Paris-Saclay. This study received funding from the French Government's "Investissement d'Avenir" program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (Grant ANR-10-LABX-62- IBEID), the MODCOV project from the Fondation de France (Grant 106059) as part of the alliance framework "Tous unis contre le virus", the University of Paris-Saclay (AAP Covid-19 2020) and the French government through its National Research Agency project SPHINX-17-CE36-0008-01. DS is also supported by a Canadian Institutes of Health Research Doctoral Foreign Study Award (Funding Reference Number 164263).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used inter-individual contact data from the i-Bird study, which obtained all authorizations in accordance with French regulations regarding medical research and information processing. All French Institutional Review Board-equivalent agencies gave the i-Bird program official approval (Comités de protection des personnes 08061; Agence française de sécurité sanitaire des produits de santé 2008-A01284-51; Comité consultatif sur le traitement de l'information en matière de recherche 08.533; Commission nationale de l'informatique et des libertés reference number AT/YPA/SV/SN/GDP/AR091118, declaration number 909036). Signed consent by patients and staff was not required according to the French Ethics Committee to which the project was submitted .I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSynthetic contact data used in CTCmodeler are available from DS within one month if requested for public research purposes. Outbreak datasets generated by CTCmodeler and surveillance outcome datasets resulting from the present study are available at https://github.com/drmsmith/agrdt/. Code developed during the present study is also available at https://github.com/drmsmith/agrdt/. https://github.com/drmsmith/agrdt/